Ieq Capital LLC Makes New $1.66 Million Investment in Turn Therapeutics Inc. $TTRX

Ieq Capital LLC bought a new stake in shares of Turn Therapeutics Inc. (NASDAQ:TTRX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 227,396 shares of the company’s stock, valued at approximately $1,660,000.

Several other hedge funds also recently modified their holdings of the business. Composition Wealth LLC acquired a new stake in shares of Turn Therapeutics during the 4th quarter worth approximately $63,000. HighTower Advisors LLC acquired a new position in Turn Therapeutics in the fourth quarter valued at approximately $78,000. Wellington Shields & Co. LLC bought a new position in Turn Therapeutics in the fourth quarter valued at approximately $259,000. Geode Capital Management LLC acquired a new stake in Turn Therapeutics during the 4th quarter worth $68,000. Finally, LPL Financial LLC acquired a new stake in Turn Therapeutics during the 4th quarter worth $51,000.

Turn Therapeutics Trading Up 0.5%

TTRX opened at $9.73 on Wednesday. The firm’s fifty day moving average is $8.59 and its two-hundred day moving average is $5.61. The firm has a market cap of $289.84 million and a PE ratio of -33.55. Turn Therapeutics Inc. has a twelve month low of $2.57 and a twelve month high of $26.50. The company has a debt-to-equity ratio of 8.83, a quick ratio of 1.19 and a current ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Equities research analysts anticipate that Turn Therapeutics Inc. will post -0.4 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on TTRX shares. Weiss Ratings downgraded Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Zacks Research upgraded Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Finally, Wall Street Zen upgraded Turn Therapeutics to a “hold” rating in a report on Saturday, July 18th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Turn Therapeutics Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.